Search research articles
Contact Us
Filters
Showing results (291-300 of 306) with videos related to
Page
of 31
Sort By:
Blood Advances
|
April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances
|
July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
American Journal of Hematology
|
March 30, 2026
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex
Nancy Gillis, Christelle Colin-Leitzinger, Yi-Han Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Ivana Gojo, Jan H Beumer, Keith W Pratz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
JAMA Oncology
|
October 12, 2023
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial
Nobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, et al.
Cancer
|
October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Blood Reviews
|
March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 306) with videos related to
Sort By:
Page
of 31
Blood Advances
|
April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances
|
July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
American Journal of Hematology
|
March 30, 2026
Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex
Nancy Gillis, Christelle Colin-Leitzinger, Yi-Han Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 10, 2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Ivana Gojo, Jan H Beumer, Keith W Pratz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
JAMA Oncology
|
October 12, 2023
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial
Nobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, et al.
Cancer
|
October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Blood Reviews
|
March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Page
of 31